Riber Back on Track with H1 Revenues of €4.4 million
Riber, a global provider of Molecular Beam Epitaxy (MBE) equipment has recorded €4.4 million in revenues over the first half of 2010, with €1.5 million for the second quarter. Not included in H1 revenues are two systems which have been produced and will be delivered during the second half of the year for a total of €4 million.
During the first half of 2010, Riber delivered two systems and finalized the production of two others, which, on account of the contractual timeframes, will be delivered during the second half of the year. At the end of June 2009, four systems had been delivered. In this context, machine sales came to €1.1 million at June 30, 2010, compared with €3.1 million at June 30, 2009.
Sales of evaporation sources and cells are down in relation to the first half of 2009 since this year's delivery schedule is concentrated over the second half of the year. The servicees and accessories business achieved record growth, up 58% compared with the first half of 2009.
On June 30, 2010, the breakdown of Riber's sales was as follows: 51% in Europe, 20% in Asia and 30% in North America.
The order book represents a record level of €16.9 million, 178% higher than on June 30, 2009. It includes 10 MBE systems, with two production systems and eight research systems. The order book also includes the largest effusion cell orders ever recorded by Riber, reflecting its arrival in the strongly growing solar and OLED sectors.
In view of the current order book, revenues are expected to total around €19 million for 2010, enabling Riber to confirm its target for profitability growth.
The first-half earnings will be announced on September 7, 2010 after close of trading.
